{"url_path":"/sec/alxo/8-k/2026-06-30/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-290447-index.html","accession_number":"0001193125-26-290447","cik":"0001810182","ticker":"ALXO","issuer_name":"ALX ONCOLOGY HOLDINGS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-290447-index.html","primary_entity_key":"0001810182","primary_entity_name":"ALX ONCOLOGY HOLDINGS INC"},"word_count":100,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn June 29, 2026, Corey Goodman, Ph.D. informed ALX Oncology Holdings Inc. (the “Company”) of his resignation as Chairman of the Company’s board of directors (the “Board”) and as a member of the Board, and from all committees thereof, to be effective as of the close of business on June 29, 2026. Dr. Goodman resigned for personal reasons and not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices."}